Pfohler et al used 3 tests to evaluate patients with malignant melanoma for evidence of melanoma-associated retinopathy (MAR). These tests identify abnormalities common in affected patients. The authors are from Saarland University in Homburg/Saar, Germany.
Tests:
(1) scotopic electroretinogram
(2) contrast sensitivity in nyctometry (nycto = dark) with or without glare
(3) visual field measurement
Parameter |
Finding |
Points |
scotopic electroretinogram |
normal |
0 |
|
abnormal (with reduced b-wave amplitudes below 110µV) |
1 |
contrast sensitivity in nyctometry |
normal |
0 |
|
contrast sensitivity better than 1:23.5 |
0 |
|
1:23.5 or worse |
1 |
visual fields |
normal |
0 |
|
one or more visual defects |
1 |
total score =
= SUM(points for all 3 tests)
Interpretation:
• minimum score: 0
• maximum score: 3
• The higher the score the more likely the patient has melanoma-associated retinopathy.
Total Score |
Group Designation |
Probability of MAR |
0 |
MS0 |
very low |
1 |
MS1 |
some suspicion |
2 |
MS2 |
moderate suspicion |
3 |
MS3 |
highly suspicious |
Specialty: Ophthalmology, Hematology Oncology
ICD-10: ,